WO2008008507A3 - Methods of treatment of diabetes - Google Patents

Methods of treatment of diabetes Download PDF

Info

Publication number
WO2008008507A3
WO2008008507A3 PCT/US2007/016023 US2007016023W WO2008008507A3 WO 2008008507 A3 WO2008008507 A3 WO 2008008507A3 US 2007016023 W US2007016023 W US 2007016023W WO 2008008507 A3 WO2008008507 A3 WO 2008008507A3
Authority
WO
WIPO (PCT)
Prior art keywords
diabetes
treatment
methods
heme
relates
Prior art date
Application number
PCT/US2007/016023
Other languages
French (fr)
Other versions
WO2008008507A2 (en
Inventor
Fritz H Bach
Maria Koulmanda
Original Assignee
Beth Israel Hospital
Fritz H Bach
Maria Koulmanda
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beth Israel Hospital, Fritz H Bach, Maria Koulmanda filed Critical Beth Israel Hospital
Publication of WO2008008507A2 publication Critical patent/WO2008008507A2/en
Publication of WO2008008507A3 publication Critical patent/WO2008008507A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/295—Iron group metal compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to the treatment, of diabetes using heme oxygenase- 1 and heme degradation products.
PCT/US2007/016023 2006-07-13 2007-07-12 Methods of treatment of diabetes WO2008008507A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83048606P 2006-07-13 2006-07-13
US60/830,486 2006-07-13

Publications (2)

Publication Number Publication Date
WO2008008507A2 WO2008008507A2 (en) 2008-01-17
WO2008008507A3 true WO2008008507A3 (en) 2008-06-19

Family

ID=38752568

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/016023 WO2008008507A2 (en) 2006-07-13 2007-07-12 Methods of treatment of diabetes

Country Status (1)

Country Link
WO (1) WO2008008507A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180015101A1 (en) * 2014-10-28 2018-01-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Compositions and methods for antigen-specific tolerance

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003088745A2 (en) * 2002-04-16 2003-10-30 James Richard Von Krosigk Composition and method for controlling spore producing fungi and bacteria

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003088745A2 (en) * 2002-04-16 2003-10-30 James Richard Von Krosigk Composition and method for controlling spore producing fungi and bacteria

Non-Patent Citations (13)

* Cited by examiner, † Cited by third party
Title
ABRAHAM NADER G ET AL: "Overexpression of human heme oxygenase-1 attenuates endothelial cell sloughing in experimental diabetes", AMERICAN JOURNAL OF PHYSIOLOGY - HEART AND CIRCULATORY PHYSIOLOGY, vol. 287, no. 6, December 2004 (2004-12-01), pages H2468 - H2477, XP002461264, ISSN: 0363-6135 *
DI PASCOLI MARCO ET AL: "Chronic CO levels has a beneficial effect on vascular relaxation in diabetes", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 340, no. 3, February 2006 (2006-02-01), pages 935 - 943, XP005234922, ISSN: 0006-291X *
GUNTHER LUKAS ET AL: "Carbon monoxide protects pancreatic beta-cells from apoptosis and improves islet function/survival after transplantation", DIABETES, vol. 51, no. 4, April 2002 (2002-04-01), pages 994 - 999, XP002461310, ISSN: 0012-1797 *
HU CHIEN-MING ET AL: "Systemic expression of heme oxygenase-1 ameliorates type 1 diabetes in NOD mice", DIABETES, vol. 56, no. 5, May 2007 (2007-05-01), pages 1240 - 1247, XP002461267, ISSN: 0012-1797 *
LI MING ET AL: "Long-lasting expression of HO-1 delays progression of type I diabetes in NOD mice", CELL CYCLE, vol. 6, no. 5, March 2007 (2007-03-01), pages 567 - 571, XP009093214, ISSN: 1538-4101 *
PILEGGI ANTONELLO ET AL: "Heme oxygenase-1 induction in islet cells results in protection from apoptosis and improved in vivo function after transplantation", DIABETES, vol. 50, no. 9, September 2001 (2001-09-01), pages 1983 - 1991, XP002461262, ISSN: 0012-1797 *
SONG F ET AL: "Induction of heme oxygenase-1 by a natural sweetener, Momordica grosvenori Swingle, attenuates the imbalance of cellular immune functions in alloxan-induced diabetes mellitus", FEBS JOURNAL, vol. 272, no. Suppl. 1, July 2005 (2005-07-01), & 30TH CONGRESS OF THE FEDERATION-OF-EUROPEAN-BIOCHEMICAL-SOCIETIES (FEBS)/9TH IUBMB CONFERENCE; BUDAPEST, HUNGARY; JULY 02 -07, 2005, pages 463 - 464, XP009093207, ISSN: 1742-464X(print) 1742-4658(ele *
TOBIASCH EDDA ET AL: "Heme oxygenase-1 protects pancreatic beta cells from apoptosis caused by various stimuli", JOURNAL OF INVESTIGATIVE MEDICINE, vol. 49, no. 6, November 2001 (2001-11-01), pages 566 - 571, XP009093164, ISSN: 1081-5589 *
VILLA M P ET AL: "Diffusing capacity for carbon monoxide in children with type 1 diabetes", DIABETOLOGIA, vol. 47, no. 11, November 2004 (2004-11-01), pages 1931 - 1935, XP002461263, ISSN: 0012-186X *
WANG HONGJUN ET AL: "Bilirubin can induce tolerance to islet allografts", ENDOCRINOLOGY, vol. 147, no. 2, February 2006 (2006-02-01), pages 762 - 768, XP002461265, ISSN: 0013-7227 *
WANG HONGJUN ET AL: "Donor treatment with carbon monoxide can yield islet allograft survival and tolerance", DIABETES, vol. 54, no. 5, May 2005 (2005-05-01), pages 1400 - 1406, XP002461311, ISSN: 0012-1797 *
WANG HONGJUN ET AL: "Heme Oxygenase-1 Expression in or Carbon Monoxide Administration only to Donor Animals Can Induce Long-term Allogeneic Islet Graft Survival in Mice", FASEB JOURNAL, vol. 18, no. 4-5, 2004, & FASEB MEETING ON EXPERIMENTAL BIOLOGY: TRANSLATING THE GENOME; WASHINGTON, DISTRICT OF COLUMBIA, USA; APRIL 17-21, 2004, pages Abst. 782.11 URL - http://ww, XP009093149, ISSN: 0892-6638 *
YE JING ET AL: "A protective role for heme oxygenase expression in pancreatic islets exposed to interleukin-1beta", ENDOCRINOLOGY, vol. 139, no. 10, October 1998 (1998-10-01), pages 4155 - 4163, XP002461261, ISSN: 0013-7227 *

Also Published As

Publication number Publication date
WO2008008507A2 (en) 2008-01-17

Similar Documents

Publication Publication Date Title
WO2007146965A3 (en) Compounds for the treatment of periodontal disease
WO2009129246A3 (en) Compositions and methods for preparing and using same
MX2009006536A (en) Organic compounds and their uses.
WO2008060374A3 (en) Methods and compositions useful for diabetic wound healing
WO2009155001A3 (en) Wnt protein signalling inhibitors
WO2009089494A3 (en) Pharmaceutical compositions
WO2007056681A3 (en) Methods for administering hypoglycemic agents
WO2008100805A3 (en) Anti-robo4 antibodies and uses therefor
TNSN08400A1 (en) Organic compounds and their uses
WO2005086656A3 (en) Heteroarylaminopyrazole derivatives useful for the treatment of diabetes
WO2009071689A3 (en) 5-halogen-substituted oxindole derivatives and use thereof for treating vasopressine-dependent diseases
WO2008070268A3 (en) Pharmaceutical compositions
WO2008079363A3 (en) Substituted tetracycline compounds for treatment of inflammatory skin disorders
WO2008066784A3 (en) Expression of foxp3 by cancer cells
EP2076134A4 (en) Compounds, screens, and methods of treatment
WO2007050348A3 (en) Potassium channel inhibitors
WO2007121125A3 (en) Hcv inhibitors
WO2008027600A3 (en) Imatinib compositions
WO2007144057A3 (en) Antimicrobial carbon
WO2007038264A3 (en) Gapr-1 methods
WO2009009034A3 (en) Methods and compositions useful in the treatment of mucositis
TNSN08496A1 (en) Aminothiazoles and their uses
WO2007079312A3 (en) Compositions and methods for treating actin-mediated medical conditions
WO2005112923A3 (en) 5-anilino-4-heteroarylpyrazole derivatives useful for the treatment of diabetes
WO2006116076A3 (en) Tab molecules

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07810461

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 07810461

Country of ref document: EP

Kind code of ref document: A2